With 0.92 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.67 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.29 whereas the lowest price it dropped to was $3.0628. The 52-week range on CVAC shows that it touched its highest point at $5.28 and its lowest point at $2.21 during that stretch. It currently has a 1-year price target of $6.60. Beta for the stock currently stands at 2.35.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CVAC was up-trending over the past week, with a rise of 23.40%, but this was up by 8.64% over a month. Three-month performance dropped to -17.01% while six-month performance rose 13.94%. The stock gained 10.47% in the past year, while it has lost -4.11% so far this year. A look at the trailing 12-month EPS for CVAC yields 0.80 with Next year EPS estimates of -0.44. For the next quarter, that number is -0.17. This implies an EPS growth rate of -173.48% for this year and 27.36% for next year.
Float and Shares Shorts:
At present, 224.34 million CVAC shares are outstanding with a float of 93.63 million shares on hand for trading. On 2025-03-31, short shares totaled 4.85 million, which was 216.0 higher than short shares on 1740700800. In addition to Dr. Alexander Zehnder M.B.A., M.D. as the firm’s CEO, MD & Member of Management Board, Mr. Axel-Sven Malkomes serves as its CFO & Member of Executive Board.
Institutional Ownership:
Through their ownership of 0.17979 of CVAC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, CVAC reported revenue of $493902000.0 and operating income of $367411000.0. The EBITDA in the recently reported quarter was $374256000.0 and diluted EPS was $1.5.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CVAC since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CVAC analysts setting a high price target of 13.688517 and a low target of 2.508236, the average target price over the next 12 months is 6.4989214. Based on these targets, CVAC could surge 318.61% to reach the target high and fall by -23.3% to reach the target low. Reaching the average price target will result in a growth of 98.74% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.85916 being high and $0.71596 being low. For CVAC, this leads to a yearly average estimate of $0.79306. Based on analyst estimates, the high estimate for the next quarter is -$0.15 and the low estimate is -$0.15. The average estimate for the next quarter is thus -$0.15.
